Protara Therapeutics, Inc. Common Stock
Symbol: TARA (NASDAQ)
3.15
▲ (1.32%) 0.041
Company Description:
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).
Key Stats
- Today's Open: $3.171
- Today's High: $3.171
- Today's Low: $3.151
- Today's Volume: 0
- Yesterday Close: $3.11
- Yesterday High: $3.18
- Yesterday Low: $3.07
- Yesterday Volume: 90.22K
- Last Min Volume: 0
- Last Min High: $3.171
- Last Min Low: $3.151
- Last Min VWAP: $0
Company Profile
- Name: Protara Therapeutics, Inc. Common Stock
- Website: https://www.protaratx.com
- Listed Date: 2020-01-10
- Location: NEW YORK, NY
- Market Status: Active
- CIK Number: 0001359931
- SIC Code: 2836
- SIC description: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
- Market Cap: $119.99M
- Round Lot: 100
- Outstanding Shares: 38.58M
- Asset Type: CS
RECENT FILINGS FOR TARA
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-08-14 | SCHEDULE 13G/A | View |
| 2025-08-14 | SCHEDULE 13G/A | View |
| 2025-08-11 | S-8 | View |
| 2025-08-11 | 10-Q | View |
| 2025-08-11 | 8-K | View |
| 2025-07-17 | SCHEDULE 13G | View |
| 2025-07-07 | 4 | View |
| 2025-06-30 | 4 | View |
| 2025-06-13 | 4 | View |
| 2025-06-13 | 4 | View |
| 2025-06-13 | 4 | View |
| 2025-06-13 | 4 | View |
| 2025-06-13 | 4 | View |
| 2025-06-13 | 4 | View |
| 2025-06-13 | 4 | View |
| 2025-06-13 | 4 | View |
| 2025-06-12 | 8-K | View |
| 2025-06-04 | 4 | View |
| 2025-06-04 | 3 | View |
| 2025-05-19 | 4/A | View |
Latest News on TARA